• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Virpax touts study results for intranasal spray for treating acute, chronic pain

February 10, 2022 By Sean Whooley

VirpaxVirpax Pharmaceuticals (NSDQ:VRPX) today announced promising results from preclinical studies for its Envelta intranasal spray.

Berwyn, Pennsylvania-based Virpax designed Envelta (NES100), an endogenous enkephalin intranasal spray, for treating acute and chronic pain, including pain associated with cancer.

According to a news release, findings from preclinical dose range-finding studies for Envelta complement previous positive preclinical toxicology results and support the company’s development of the potential non-addictive treatment for pain. The company is currently conducting FDA investigational new drug (IND) enabling studies under a cooperative research and development agreement with the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS).

NCATS conducted a 14-day intranasal dose range-finding toxicity study of Envelta in rats with a 14-day recovery period, showing no adverse related findings in hematology, coagulation and serum chemistry data. Another study of Envelta in dogs showed no adverse toxicologic findings.

Further evaluations of Envelta will be completed by NCATS to support the submission of an IND application to the FDA, Virpax said.

Envelta uses a preassembled device and cartridge to propel the enkephalin formulation through the nose to the brian by flowing along the olfactory nerve pathway, with Virpax’s molecular envelope technology designed to protect the drug and help carry it to the brain across the blood-brain barrier.

“These preclinical data support and further strengthen the development of Envelta as a potential intranasal enkephalin for the management of cancer and non-cancer pain,” Virpax Chairman and CEO Anthony P. Mack said in the release. “We remain focused on the next steps so that we may submit an IND and then initiate a Phase 1 study in humans upon any potential FDA acceptance.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Preclinical Trials Tagged With: Virpax Pharmaceuticals

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS